Hanmi acquired approval of ‘Amosartan Plus,’ 3-substance combination therapy for treatment of hypertension
Hanmi Pharm(CEO Jong-Soo Woo, Sae-Chang Kwon) announced ‘Amosartan Plus,’ a 3-substance combination drug for the treatment of hypertension, acquired commercialization approval from the Ministry of Health and Welfare(MOHW) on the 29th.
Amosartan Plus, the world’s first global combination drug of ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
